These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24333732)

  • 21. Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells.
    Oh B; Kim TY; Min HJ; Kim M; Kang MS; Huh JY; Kim Y; Lee DS
    Anticancer Drugs; 2013 Jan; 24(1):20-31. PubMed ID: 23075630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic anticancer activity of Thiazolo[5,4-b]quinoline derivative D3CLP in combination with cisplatin in human cervical cancer cells.
    González-Sánchez I; Lira-Rocha A; Navarrete A; Loza-Mejía MA; Coronel-Cruz C; Mendoza-Rodríguez CA; Cerbón MA
    Anticancer Res; 2012 Dec; 32(12):5159-65. PubMed ID: 23225412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
    Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro.
    Zhang P; Gao WY; Turner S; Ducatman BS
    Mol Cancer; 2003 Jan; 2():1. PubMed ID: 12537587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines.
    Kübler HR; van Randenborgh H; Treiber U; Wutzler S; Battistel C; Lehmer A; Wagenpfeil S; Hartung R; Paul R
    Prostate; 2005 Jun; 63(4):385-94. PubMed ID: 15617027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation.
    Ikenberg K; Valtcheva N; Brandt S; Zhong Q; Wong CE; Noske A; Rechsteiner M; Rueschoff JH; Caduff R; Dellas A; Obermann E; Fink D; Fuchs T; Krek W; Moch H; Frew IJ; Wild PJ
    J Pathol; 2014 Oct; 234(2):239-52. PubMed ID: 24930886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome.
    Luo L; Zeng J; Liang B; Zhao Z; Sun L; Cao D; Yang J; Shen K
    Exp Mol Pathol; 2011 Oct; 91(2):596-602. PubMed ID: 21787767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro.
    Yerushalmi R; Nordenberg J; Beery E; Uziel O; Lahav M; Luria D; Fenig E
    Exp Oncol; 2007 Jun; 29(2):126-31. PubMed ID: 17704745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
    Kamat AA; Merritt WM; Coffey D; Lin YG; Patel PR; Broaddus R; Nugent E; Han LY; Landen CN; Spannuth WA; Lu C; Coleman RL; Gershenson DM; Sood AK
    Clin Cancer Res; 2007 Dec; 13(24):7487-95. PubMed ID: 18094433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer.
    Dai D; Holmes AM; Nguyen T; Davies S; Theele DP; Verschraegen C; Leslie KK
    Cancer Res; 2005 Oct; 65(20):9517-24. PubMed ID: 16230417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate.
    Mitsuhashi T; Nakayama M; Sakurai S; Fujimura M; Shimizu Y; Ban S; Ogawa F; Hirose T; Ishihara O; Shimizu M
    Ann Diagn Pathol; 2007 Feb; 11(1):49-54. PubMed ID: 17240308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD117 (c-kit) expression in human hepatocellular carcinoma.
    Becker G; Schmitt-Graeff A; Ertelt V; Blum HE; Allgaier HP
    Clin Oncol (R Coll Radiol); 2007 Apr; 19(3):204-8. PubMed ID: 17359908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer.
    Yokoyama T; Enomoto T; Serada S; Morimoto A; Matsuzaki S; Ueda Y; Yoshino K; Fujita M; Kyo S; Iwahori K; Fujimoto M; Kimura T; Naka T
    Int J Cancer; 2013 Jan; 132(2):472-84. PubMed ID: 22729361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blocking NOTCH pathway can enhance the effect of EGFR inhibitor through targeting CD133+ endometrial cancer cells.
    Shang C; Lang B; Meng LR
    Cancer Biol Ther; 2018 Feb; 19(2):113-119. PubMed ID: 27791463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic effects of imatinib (STI 571) in combination with chemotherapeutic drugs in head and neck cancer.
    Bruce IA; Slevin NJ; Homer JJ; McGown AT; Ward TH
    Anticancer Drugs; 2005 Aug; 16(7):719-26. PubMed ID: 16027519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MLH1 enhances the sensitivity of human endometrial carcinoma cells to cisplatin by activating the MLH1/c-Abl apoptosis signaling pathway.
    Li Y; Zhang S; Wang Y; Peng J; Fang F; Yang X
    BMC Cancer; 2018 Dec; 18(1):1294. PubMed ID: 30594176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.
    Kwak Y; Cho H; Hur W; Sim T
    Mol Cancer Ther; 2015 Oct; 14(10):2292-302. PubMed ID: 26294741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo.
    Yasukawa M; Fujihara H; Fujimori H; Kawaguchi K; Yamada H; Nakayama R; Yamamoto N; Kishi Y; Hamada Y; Masutani M
    Int J Mol Sci; 2016 Feb; 17(3):272. PubMed ID: 26927065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pro-chemotherapeutic effects of antibody against extracellular domain of claudin-4 in bladder cancer.
    Kuwada M; Chihara Y; Luo Y; Li X; Nishiguchi Y; Fujiwara R; Sasaki T; Fujii K; Ohmori H; Fujimoto K; Kondoh M; Kuniyasu H
    Cancer Lett; 2015 Dec; 369(1):212-21. PubMed ID: 26342407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs.
    Patwardhan PP; Surriga O; Beckman MJ; de Stanchina E; Dematteo RP; Tap WD; Schwartz GK
    Clin Cancer Res; 2014 Jun; 20(12):3146-58. PubMed ID: 24718867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.